GraceFinance · Source-backed public company research
Tarsus Pharmaceuticals, Inc. (TARS)
Nasdaq · Manufacturing · Biological Products, (No Diagnostic Substances)
Core research established · 4/4 core data layers currently established
What Tarsus Pharmaceuticals, Inc. does
Overview We are a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. We launched XDEMVY® (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, for the treatment of Demodex blepharitis, in August 2023 after receiving U.S. Food and Drug Administration (“FDA”) approval in July 2023. Demodex blepharitis is caused by the infestation of Demodex mites. Demodex blepharitis (“blephar” is a reference to eyelid and “itis” is a reference to inflammation) is a disease characterized by inflammation of the eyelid margin, redness and ocular irritation, including a specific type of eyelash dandruff called collarettes, which are pathognomonic for Demodex blepharitis.
Open the company story
The live GraceFinance page shows source-backed financial changes, management context, guidance, confirmed events, risks, and connected history only when the applicable evidence and relationships have been established. Missing research stays visible instead of being inferred.